NDAORALTABLET
Approved
Jul 1944
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dicumarol is an oral anticoagulant tablet approved in 1944 as a coumarin-derivative anticoagulant. It prevents blood clot formation by inhibiting vitamin K-dependent clotting factors. This legacy drug was historically used for thromboembolic disorders but has largely been superseded by warfarin and newer anticoagulants.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal market presence, this brand operates with a small team focused on regulatory maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on dicumarol as a career opportunity is limited; the product generates no linked job openings and operates with a maintenance-focused team at AbbVie. This role is suitable for professionals seeking stable, low-pressure regulatory or compliance work rather than commercial growth or innovation-driven career advancement.
Regulatory Affairs SpecialistCompliance Officer
Worked on DICUMAROL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.